Zimmer Biomet (NYSE:ZBH) Stock Gets Price Target Increase from JPMorgan Chase & Co.

Zimmer Biomet (NYSE:ZBH) had its price objective upped by investment analysts at JPMorgan Chase & Co. from $117.00 to $120.00 in a note issued to investors on Thursday, Benzinga reports. The firm presently has a “neutral” rating on the medical equipment provider’s stock. JPMorgan Chase & Co.‘s target price would suggest a potential upside of 12.07% from the stock’s previous close.

Other equities research analysts have also recently issued reports about the company. Zacks Research upgraded Zimmer Biomet from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 25th. Truist Financial set a $114.00 price objective on shares of Zimmer Biomet in a research report on Thursday. Citigroup boosted their price objective on shares of Zimmer Biomet from $99.00 to $117.00 and gave the company a “neutral” rating in a research note on Thursday. UBS Group reaffirmed a “buy” rating and set a $120.00 target price on shares of Zimmer Biomet in a report on Thursday, August 6th. Finally, Sanford C. Bernstein upped their target price on shares of Zimmer Biomet from $93.00 to $107.00 and gave the stock a “market perform” rating in a report on Thursday. Seven analysts have rated the stock with a Buy rating, sixteen have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Zimmer Biomet presently has an average rating of “Hold” and a consensus target price of $111.42.

Zimmer Biomet Price Performance

ZBH traded down $3.07 during trading on Thursday, reaching $107.08. 3,623,755 shares of the company were exchanged, compared to its average volume of 2,266,789. The company’s 50-day moving average is $94.90 and its two-hundred day moving average is $91.89. The company has a market cap of $20.42 billion, a price-to-earnings ratio of 26.05, a P/E/G ratio of 2.33 and a beta of 0.50. The company has a quick ratio of 0.94, a current ratio of 1.69 and a debt-to-equity ratio of 0.50. Zimmer Biomet has a 12-month low of $79.12 and a 12-month high of $112.54.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Wednesday, November 4th. The medical equipment provider reported $1.90 EPS for the quarter, topping the consensus estimate of $1.88 by $0.02. The business had revenue of $2.06 billion during the quarter, compared to the consensus estimate of $2.04 billion. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%. The firm’s revenue was up 3.1% compared to the same quarter last year. During the same quarter last year, the company earned $1.90 EPS. Research analysts forecast that Zimmer Biomet will post 8.54 earnings per share for the current fiscal year.

Insider Activity at Zimmer Biomet

In other news, insider Chad F. Phipps sold 3,000 shares of the stock in a transaction on Friday, September 4th. The shares were sold at an average price of $98.35, for a total value of $295,050.00. Following the transaction, the insider owned 65,231 shares of the company’s stock, valued at $6,415,468.85. This represents a 4.40% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Kevin R. Thornal sold 5,691 shares of the stock in a transaction on Friday, September 11th. The stock was sold at an average price of $92.95, for a total transaction of $528,978.45. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 1.28% of the company’s stock.

Institutional Trading of Zimmer Biomet

A number of hedge funds have recently made changes to their positions in ZBH. BlackRock Inc. bought a new position in Zimmer Biomet in the second quarter valued at $1,344,282,000. State Street Corp raised its position in Zimmer Biomet by 0.6% during the second quarter. State Street Corp now owns 8,877,171 shares of the medical equipment provider’s stock valued at $766,343,000 after purchasing an additional 52,044 shares in the last quarter. Primecap Management Co. CA bought a new stake in Zimmer Biomet during the second quarter worth about $328,578,000. Dimensional Fund Advisors LP lifted its stake in Zimmer Biomet by 1.1% during the first quarter. Dimensional Fund Advisors LP now owns 2,224,163 shares of the medical equipment provider’s stock worth $201,082,000 after purchasing an additional 24,208 shares during the last quarter. Finally, Bank of America Corp DE bought a new stake in Zimmer Biomet during the second quarter worth about $187,480,000. 88.89% of the stock is owned by institutional investors.

Key Zimmer Biomet News

Here are the key news stories impacting Zimmer Biomet this week:

• Positive Sentiment: Third-quarter sales rose 3.1% to $2.063 billion, while adjusted EPS of $1.90 topped estimates of $1.88. The company also raised its full-year 2026 outlook; stronger hips and S.E.T. sales helped offset knee-market weakness. Zimmer Biomet Announces Third Quarter 2026 Financial Results
• Positive Sentiment: Royal Bank of Canada raised its target to $125 and upgraded ZBH to “outperform,” providing a bullish signal. Royal Bank of Canada recommendations
• Neutral Sentiment: Citigroup lifted its target to $117 but kept a “neutral” rating. Wells Fargo raised its target to $113 and maintained “equal weight.” Citigroup recommendations Wells Fargo recommendations
• Negative Sentiment: Reported diluted EPS fell 13.8% to $1.00, while adjusted EPS was flat year over year. Knee weakness and margin pressure remain concerns; Bernstein raised its target to $107 but kept a “market perform” rating. Zimmer Biomet Q3 Profit Falls, Lifts FY26 Outlook

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc is a medical technology company that develops and manufactures products used in orthopedic surgery and musculoskeletal care. Its portfolio includes implants for the hip, knee, shoulder, and other joints, as well as products for sports medicine, extremity reconstruction, trauma, and spine procedures.

The company also offers surgical technologies and solutions designed to support orthopedic procedures, including robotic-assisted surgery systems, digital tools, patient-specific planning, and related instruments.